7Baggers
 Bolt Biotherapeutics Reports Improved Financial Performance  TipRanks Thu, 13 Nov 2025 04:22:36 GMT
 Bolt Biotherapeutics reports Q3 EPS ($3.72), consensus ($5.39)  TipRanks Wed, 12 Nov 2025 22:41:51 GMT
 BOLT Exceeds Q3 Revenue Expectations and Advances Cancer Treatme  GuruFocus Wed, 12 Nov 2025 22:34:41 GMT
 Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot  San Antonio Express-News Wed, 12 Nov 2025 21:54:55 GMT
 Bolt Biotherapeutics Q3 collaboration revenue doubles  TradingView Wed, 12 Nov 2025 21:38:30 GMT

Bolt Biotherapeutics, Inc
(NASDAQ:BOLT) 

BOLT stock logo

Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tum...

Founded: 2015
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends